AFP and hepatocellular carcinoma: In patients with HCC who were negative for HBV DNA, when PIVKA-II combined with AFP was used to diagnose HBVDNA−/HCC, the AUROC of PIVKA-II decreased (0.863 and 0.895, respectively).